Atara Biotherapeutics Inc
ATRA
Company Profile
Business description
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Contact
1280 Rancho Conejo Boulevard
Suite 200
Thousand OaksCA91320
USAT: +1 805 623-4211
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
ASX healthcare giant remains well positioned despite share slump
We welcome the CEO change at CSL but relatively soft plasma performance will postpone recovery
stocks
Australian bank remains overvalued despite strong result
When strong fundamentals meet persistent valuation headwinds.
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
The latest take from our equity research analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 41.30 | -0.44% |
| CAC 40 | 8,403.89 | 90.65 | 1.09% |
| DAX 40 | 25,157.55 | 301.40 | 1.21% |
| Dow JONES (US) | 49,451.98 | 669.42 | -1.34% |
| FTSE 100 | 10,463.00 | 9.11 | -0.09% |
| HKSE | 27,032.54 | 233.84 | -0.86% |
| NASDAQ | 22,597.15 | 469.32 | -2.03% |
| Nikkei 225 | 57,639.84 | 10.70 | -0.02% |
| NZX 50 Index | 13,489.17 | 42.31 | -0.31% |
| S&P 500 | 6,832.76 | 108.71 | -1.57% |
| S&P/ASX 200 | 9,043.50 | 18.50 | -0.20% |
| SSE Composite Index | 4,134.02 | 2.03 | 0.05% |